Nagae T, Louie A Y, Aizawa K, Ishimaru S, Wilson S E
Department of Surgery, Tokyo Medical College Hospital, Japan.
J Cardiovasc Surg (Torino). 1998 Dec;39(6):709-15.
Photosensitizers, such as Photofrin II or Chloroaluminum-sulfonated phthalocyanine accumulate at sites of arterial injury. We have exploited this property to develop a model of photodynamic therapy (PDT) for intimal hyperplasia. The fluorescent probe [maleylated-bovine serum albumin (mal-BSA) conjugated with Texas-red] can be selectively targeted to intimal macrophages and smooth muscle cells recruited during formation of hyperplasia via a receptor-mediated mechanism.
In this study, the photosensitizer chlorin e6 (Cle6) was conjugated to mal-BSA in a rat model of intimal hyperplasia, then tested the efficacy of the ligand conjugation to photosensitizer (mal-BSA/Cle6) in PDT of intimal hyperplasia. Arterial wall injury was produced by a balloon catheter pulled through the abdominal aorta of the rat to create a model of intimal hyperplasia. Fluorescent compounds were injected two weeks after injury.
Four hours after injection, the intensity of fluorescence achieved with injection of mal-BSA/Cle6 was higher for intimal hyperplastic lesions as compared to control areas. BSA-Cle6 unconjugated did not demonstrate such delivery. Two weeks after balloon injury, the injured aorta was irradiated externally with an argon pumped dye laser four hours following the photosensitizer injection. We employed two total radiant exposures: 20 J/cm2 and 40 J/cm2. Forty-eight hours after PDT, the arteries were examined histologically. Intimal hyperplastic cells were significantly reduced by PDT in the mal-BSA/Cle6 injected group (40-100%) versus the Cle6 group (0-20%).
Mal-BSA/Cle6 is taken up efficiently by a scavenger pathway, localizes in areas of intimal hyperplasia, and functions as a photosensitizer for PDT.
光敏剂,如血卟啉衍生物(Photofrin II)或氯铝磺化酞菁,会在动脉损伤部位蓄积。我们利用这一特性开发了一种针对内膜增生的光动力疗法(PDT)模型。荧光探针[与德克萨斯红偶联的马来酰化牛血清白蛋白(mal-BSA)]可通过受体介导机制选择性地靶向增生形成过程中募集的内膜巨噬细胞和平滑肌细胞。
在本研究中,在内膜增生大鼠模型中将光敏剂氯e6(Cle6)与mal-BSA偶联,然后测试配体偶联光敏剂(mal-BSA/Cle6)在内膜增生光动力疗法中的疗效。通过将球囊导管经大鼠腹主动脉牵拉造成动脉壁损伤,以建立内膜增生模型。损伤两周后注射荧光化合物。
注射后四小时,与对照区域相比,注射mal-BSA/Cle6后内膜增生病变处的荧光强度更高。未偶联的BSA-Cle6未表现出这种递送效果。球囊损伤两周后,在注射光敏剂四小时后,用氩泵浦染料激光对外照射受损主动脉。我们采用了两种总辐射剂量:20 J/cm²和40 J/cm²。光动力疗法后48小时,对动脉进行组织学检查。与Cle6组(0 - 20%)相比,注射mal-BSA/Cle6组的内膜增生细胞通过光动力疗法显著减少(40 - 100%)。
Mal-BSA/Cle6通过清除剂途径有效摄取,定位于内膜增生区域,并作为光动力疗法的光敏剂发挥作用。